Related Experiment Video

Updated: Dec 3, 2025

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.4K

Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer

Che-Pei Kung1, Kyle A Cottrell1, Sua Ryu1

  • 1Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.

Oncogene
|October 28, 2020
PubMed

Insights

Triple-negative breast cancer (TNBC) is deadly due to lack of targeted therapies. ADAR1 enzyme is crucial for TNBC cell survival and proliferation, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Biology

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies, contributing to its high mortality.
  • The ADAR1 enzyme, involved in RNA editing, is upregulated in various cancers, including TNBC.

Purpose of the Study:

  • To investigate the role of ADAR1, specifically its p150 isoform, in TNBC cell survival and proliferation.
  • To explore ADAR1 as a potential therapeutic target for TNBC.

Main Methods:

  • Knockdown of ADAR1 in TNBC cell lines.
  • Assessment of proliferation, tumorigenesis, and translational repression.
  • Analysis of interferon-stimulated gene expression and IFNAR1 signaling.

Main Results:

  • ADAR1 expression, particularly the p150 isoform, is essential for TNBC cell line survival.
  • ADAR1 knockdown significantly reduced TNBC cell proliferation and tumorigenesis.
  • Loss of ADAR1 function induced translational repression and elevated interferon-stimulated gene expression, which was partially rescued by reducing IFNAR1.

Conclusions:

  • ADAR1 plays a critical role in maintaining the viability and proliferation of TNBC cells.
  • Targeting ADAR1 presents a promising novel therapeutic strategy for treating triple-negative breast cancer.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K